Acumen Pharmaceuticals (ABOS) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 11.7% versus a loss of 22.1%. Over five years, IPHA leads with a -74.1% price change compared with -84.5% for ABOS. Innate Pharma S.A. is the larger company by market cap ($165.3 million vs $151.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | IPHA |
|---|---|---|
| Share price | $2.10 | $1.48 |
| Market cap | $151.87M | $165.32M |
| 1-day change | 0.00% | -2.63% |
| YTD return | -0.47% | -13.14% |
| 1-year return | +11.70% | -22.05% |
| 5-year return | -84.50% | -74.11% |
| EPS (TTM) | $-1.64 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.71 |
| 52-week low | $1.50 | $1.17 |
| Distance from 52-week high | -41.67% | -45.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.90% | +350.68% |
| Average volume | 435.44K | 156.71K |
| Shares outstanding | 72.32M | 111.70M |
| Employees | 60 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed IPHA by 33.8 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
ABOS vs IPHA FAQ
Which is bigger, Acumen Pharmaceuticals or Innate Pharma S.A.?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $165.32M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or IPHA?
ABOS returned +11.70% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.